H1 2026 Interim Results Presentation August 20, 2026 ASX: TLX | NASDAQ: TLX Radiopharmaceutical manufacturing suite at TMS North Melbourne.

Presenters Agenda CEO remarks1 Therapeutics update 2 Financial update 3 Precision Medicine update 4 Q&A 2 5 Dr. Christian Behrenbruch Managing Director and Group CEO Darren Smith Group Chief Financial Officer Kevin Richardson CEO, Telix Precision Medicine Dr. David N. Cade Chief Medical Officer

This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this presentation are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this presentation, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in this presentation. This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Telix’s actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. This presentation also contains estimates and other statistical data made by independent parties and by Telix relating to market size and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of Telix’s future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk. Use of Non-IFRS Measures. Telix’s results are reported under International Financial Reporting Standards (IFRS). This announcement includes various non-IFRS financial information to reflect its underlying performance, which have not been subject to audit or review. These non-IFRS measures include Adjusted EBITDA, which represents net earnings attributable to the Group excluding finance costs, income tax expense, depreciation and amortization, remeasurement of provisions, other income and expenses. As required by SEC rules, we have provided reconciliations of these non-IFRS financial measures to the most directly comparable IFRS measures, which for Adjusted EBITDA, is Profit/(loss) before income tax. The Group believes that these non-IFRS measures, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders with additional useful information on the underlying trends, performance and position of the Group and are consistent with how business performance is measured internally. The non-IFRS measures are not defined by IFRS and therefore may not be directly comparable with other companies’ alternative performance measures. Telix’s first generation PSMA-PET imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA. Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab (marketed under the brand name Scintimun®) is approved in 32 European countries and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the EEA. Registrations vary country to country. Refer to your local approved label or regulatory authority status for full information. No other Telix drug or device has received marketing authorization in any jurisdiction. Any other Telix drug or device that is discussed in this presentation, including Zircaix and Pixclara, is investigational or under development and not approved by any regulatory authority. The efficacy or safety profile of any unapproved drug or device has not been determined by any regulatory authority. In addition, Zircaix and Pixclara brand names and launch are subject to final regulatory approval. All trademarks and trade names referenced in this presentation are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2026 Telix Pharmaceuticals Limited. All rights reserved. 3 Forward looking statement

CEO remarks Dr. Christian Behrenbruch Managing Director and Group CEO

Delivering against our 2026 strategic priorities 5 Continue commercial growth Secured Prescription Drug User Fee Act date for Pixclara®1, September 11, 20262 Pixlumi®1 Marketing Authorization Application accepted for review in Europe3 Advancing Phase 3 therapeutics programs: • TLX591-Tx ProstACT Global: FDA alignment on safety and Part 2 Protocol in mCRPC4 • TLX101-Tx IPAX BrIGHT5: dosing patients with recurrent glioblastoma • TLX250-Tx LUTEON: dosing patients with advanced ccRCC6 TLX090-Tx7 SOLACE: dosing patients BiPASS 8 nearing completion of enrollment 2 3 On track to deliver in line with upper end of FY 2026 revenue guidance of $950M - $970M 1 Delivered $388M in sales in H1 2026 for Illuccix® and Gozellix®, up 27% YoY Illuccix® available in 22 countries, including 17 in Europe Launch new products Advance five late-stage clinical programs Strong execution across commercial, regulatory and clinical milestones 1. Launch and brand names subject to final regulatory approval. Zircaix (TLX250-Px, ccRCC imaging), Pixclara and Pixlumi (TLX101-Px, glioma imaging). 2. Telix ASX disclosure April 10, 2026. 3. Telix media release May 1, 2026. 4. Telix ASX disclosure July 2, 2026. ClinicalTrials.gov ID: NCT06520345, metastatic castration- resistant prostate cancer. 5. ClinicalTrials.gov ID: NCT07100730. 6. ClinicalTrials.gov ID: NCT07197580. Phase 3 study in Australia, phase 2a study in U.S./Europe. Clear cell renal cell carcinoma. 7. ClinicalTrials.gov ID: NCT07197645. 8. ClinicalTrials.gov ID: NCT07052214.

Continued commercial execution delivering growth Delivered 22% YoY revenue growth Group revenue US$M 56% 6 Market-leading position reinforced by differentiated products • Group revenue increased by 22% to $477M driven by strong demand across our Precision Medicine portfolio • Global revenue (ex-TMS) increased to $388M, up 25% YoY driven by Precision Medicine business market share gains • Diversified revenue streams through TMS ($89M1) and international expansion TMS = Telix Manufacturing Solutions. 1. TMS revenue from third parties. RLS is the largest component of TMS, contributing to third party revenue. Excludes revenues from Illuccix and Gozellix sold through RLS. 2. Includes $4M payment from China Grand Pharma collaboration. 3. Includes $5M payment from China Grand Pharma collaboration. 310 322 388 H1 2024 H2 2024 H1 2025 H2 2025 H1 2026 240 277 390 414 477 Global revenue excluding TMS TMS revenue1 22% 25% 2 3

Investments that expand our growth opportunities Doubling the TAM by an incremental ~800,000+ scans per year2 and aiming to change the standard-of-care New indication for diagnosis of brain metastasis, expanding the TAM by an incremental 100,000+ scans per year4 New, small molecule candidate, TLX597-Tx with potentially best-in-class therapeutic profile5 Two ongoing Phase 2 studies: OPTIMAL-PSMA6 in mCRPC and OPTIMAL-e7 to position the molecule for mHSPC Entered into a co-development and co- commercialization agreement with Regeneron to develop next-generation candidates8 TAM = Total addressable market, mHSPC = metastatic hormone sensitive prostate cancer. 1. Clinicaltrials.gov NCT07052214. 2. Based on positive scans for PI-RADS 2-4 (NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2025), includes negative scans at a ratio of 3.1 scan per positive case (Landa et al. PLOS ONE. 2024). 3. Launch and brand name subject to final regulatory approval. 4. Based on internal estimates. 5. Presented at International Prostate Cancer Symposium, IPCS April 29, 2026. 6. Telix media release April 30, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437. 7. Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336. 8. Telix ASX announcement April 12, 2026. Increased R&D investments to drive meaningful growth EXPANDING INTO NEW INDICATIONS EXPANDING THE PIPELINE 7 3 1

Expanding our manufacturing capabilities 8 1. Telix Innovations Brazil, Ltda., joint venture with R2PHARMA, a subsidiary of GSH Corp Participações S.A. (Grupo GSH), Telix as 51% owner. 2. Partnership with Grand Pharmaceutical Group Limited (Grand Pharma) for the Greater China region. 3. Good Manufacturing Practice. Multiple RLS sites in the U.S. Adding therapy lines at select RLS sites Strategic partner1,2 TMS site Yokohama, Japan ARTMS QIS® for isotope production ARTMS QIS® technology, enabling highly efficient, cost-effective isotope production Sacramento, U.S. New facility in Melbourne, Australia Clinical manufacturing, radiotracer administration and imaging Seneffe, Belgium GMP3 capacity to deliver therapeutics Accelerating growth, de-risking execution and positioning for therapeutic launches

Financial update Darren Smith Chief Financial Officer

H1 2026 Key financial metrics Strong financial performance across growth, profitability and cash generation Revenue up 22% YoY1 $477M ($390M H1 2025) R&D 26% of revenue1 Net profit up $41M YoY1 $38M ($-2M H1 2025) Cash balance up 78% $252M (Dec 31 2025: $142M) $124M ($82M H1 2025) EBITDA1 up 146% YoY $52M ($21M H1 2025) Precision Medicine Gross margin up 1% YoY 65% (64% H1 2025) 10 1. Refers to Group Income Statement. EBITDA refers to adjusted group earnings before interest, tax, depreciation and amortization. Net profit refers to Net profit after tax.

• Gross margin (GM) of 55%, increased 2% YoY driven by disciplined pricing, manufacturing & distribution efficiencies • R&D investments up 51% YoY, driven by progress on four late-stage programs1. Increased investment enabled by strong commercial execution and initial payment by Regeneron2 • Operating expenses3 reduced by 1% as % of revenue driven by expense control • Operating profit of $46M, reflecting robust revenue growth, initial payment from Regeneron and disciplined cost management H1 2026 Income statement (Group) Strong execution driving 22% revenue growth and 148% EBITDA expansion YoY 1. ProstACT Global, Phase 3 study NCT 06520345, LUTEON, Phase 2/3 study, NCT 07197580, IPAX BrIGHT, Phase 3 study NCT 07100730, BiPASS, Phase 3 study NCT 07052214. 2. Other income refers to an upfront payment of $40M from Regeneron. 3. Operating expenses comprises S&M, G&A, M&D. 11 H1 2026 % of revenue H1 2025 % of revenue YoY changeUS$M US$M Revenue 477 390 22% Cost of sales (217) (181) 20% Gross profit 260 55% 209 53% 24% Other income 40 8% — — * Research and development (R&D) (124) (26)% (82) (21)% 51% Operating expenses (136) (29)% (116) (30)% 17% Other gains/(losses) 6 1% (1) — * Operating profit 46 10% 10 3% 360% Finance income 2 — 4 1% (50)% Finance costs (19) (4)% (19) (5)% — Profit/(loss) before tax 29 6% (5) (1)% * Adjusted EBITDA 52 11% 21 5% 148% * Percentage not meaningful

Strong revenue generation provides flexibility to reinvest Discretionary R&D investment driving new growth opportunities 1. TMS revenue from third parties. RLS is the largest component of Telix Manufacturing Solutions, TMS, contributing to third party revenue. Excludes revenues from Illuccix and Gozellix sold through RLS. 12

Precision Medicine delivering growth and high margins A highly profitable business delivering 26% YoY EBITDA growth 1. Cost of sales includes intersegment distribution fees of $12M (H1 2025: $6M). 2. Launch and brand names subject to final regulatory approval. 3. Refers to Adjusted EBITDA. 13 • Revenue increased by 27% to $388M, driven by continued adoption of Illuccix and Gozellix across all markets • Strong demand supported by differentiated products, reimbursement strategy and global expansion • Gross margin expanded 1% YoY to 65%1, reflecting a favorable product mix and disciplined pricing strategy • R&D investments up 42% YoY driven by Pixclara2, Zircaix2 and BiPASS to deliver near- term growth • Delivered EBITDA3 growth of 26% YoY to $132M, while continuing to reinvest in key, near- term pipeline initiatives H1 2026 % of revenue H1 2025 % of revenue YoY change US$M US$M Revenue 388 306 27% Cost of sales (134) (109) 23% Gross profit 254 65% 197 64% 29% Research and development (R&D) (54) (14)% (38) (12)% 42% Operating expenses (69) (18)% (56) (18)% 23% Other gains/(losses) (net) 1 — (2) (1)% * Operating profit 132 34% 101 33% 29% Adjusted EBITDA 132 34% 105 34% 26% * Percentage not meaningful

Telix Manufacturing Solutions (TMS) 1. Prior period comparisons reflect RLS results since acquisition close as of January 28, 2025. 2. Internal revenue is eliminated on consolidation. Investment in manufacturing and supply chain to scale up operations 14 • TMS generated $89M of third-party revenue, up 10% YoY1, primarily driven by RLS • RLS drove manufacturing and supply chain efficiencies, with internal revenue up 73% YoY to $57M2 • $23M EBITDA impact driven by targeted investments in future therapeutic growth • Seneffe GMP capacity build-out for therapeutic candidates • Yokohama, ARTMS QIS® installation to support isotope production • RLS expansion to add therapy manufacturing lines H1 2026 % of revenue H1 2025 % of revenue YoY US$M US$M Change External revenue 89 81 10% Internal revenue 57 33 73% Cost of sales (138) (103) 34% Gross profit 8 5% 11 10% (27)% Research and development (R&D) (3) (2)% (3) (3)% —% Operating expenses (38) 28% (28) 27% 36% Operating loss (33) (23)% (20) (18)% 65% Adjusted EBITDA (loss) (23) (16)% (13) (11)% 77%

Group revenue US$MRevenue guidance range: $950M to $970M1 • Based on approved products and geographies • ~25% growth in Precision Medicine revenue • Potential upside pending regulatory approvals • Revenue is expected to come in at the upper end of guidance R&D guidance range: $230M to $270M • Pipeline expansion: TLX597-Tx • Research collaboration with Regeneron • Pixclara2 indication expansion • BiPASS study expansion We will continue reinvesting our earnings to position the Company for long-term growth 15 2022 2023 2024 2025 2026 107 333 517 804 950-970 Actuals Full Year guidance Guidance is based on expected global and domestic economic conditions and subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. See Disclaimer for more information. 1. Excludes $40 million non-refundable other income received from Regeneron. 2. Launch and brand names subject to final regulatory approval. FY 2026 guidance Continued growth trajectory

Precision Medicine update Kevin Richardson Precision Medicine, CEO

17 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 150 154 155 186 1% 161 202 3% 4% 16% 9% 31% Precision Medicine Global Sales US$M Precision Medicine portfolio delivered 31% YoY growth and 9% QoQ growth

Global infrastructure buildout to enable therapeutic launches 18 1. Australia, Brazil, U.S., Canada, UK, Ireland, France, Spain, Germany, Italy, Portugal, Belgium, Netherlands, Luxembourg, Norway, Sweden, Denmark, Finland, Austria, Czech Republic, Slovakia, Cyprus, Greece, Malta. 2. Australia, Brazil, U.S., Canada, UK, Ireland, France, Spain, Germany, Italy, Portugal, Belgium, Netherlands, Luxembourg, Norway, Sweden, Denmark, Finland, Austria, Czech Republic, Slovakia, Switzerland. Temporary supply in Switzerland due to local shortages. 3. Telix media release January 19, 2026. ClinicalTrials.gov ID: NCT05847348. 4. Telix media release July 17, 2026. Japan Registry of Clinical Trials identifier: JRCT2031250473. Global approvals and launches on track • Illuccix has marketing authorizations in 24 countries1 • Commercially available in 22 countries2 • Completed Phase 3 study in China - NDA under review3 • Completed patient enrollment in Phase 3 study in Japan4 Building a global footprint with regulators, customers and payers

Two first-in-class imaging agents for glioma and renal masses potentially first to market1,2 PDUFA date: September 11, 2026, Pixlumi ®3 MAA accepted in Europe Included in National Comprehensive Cancer Network (NCCN®) guidelines Inclusion in International guidelines: EANM/EANO/RANO/SNMMI Expanding into new indication: brain metastases4 Potentially first to market (U.S.)1 for imaging of gliomas BLA resubmission in progress Breakthrough Therapy Designation and Fast Track Designation Inclusion in the International guidelines: SNMMI, EANM and ACNM for molecular imaging of renal masses Potentially first radiolabeled biologic to market1 for imaging of renal masses PDUFA = Prescription Drug User Fee Act. MAA = Marketing authorization application. EANM = European Association of Nuclear Medicine. EANO = European Association of Neuro-Oncology. RANO = Response Assessment in Neuro-Oncology. SNMMI = Society of Nuclear Medicine and Molecular Imaging. BLA = Biologics License Application. ACNM = American College of Nuclear Medicine. 1. Subject to FDA approval. 2. First to market for Pixclara refers to the U.S. 3. Launch and brand names subject to final regulatory approval. 4. ASX release July 20, 2026. 19

PSMA-PET scans (in thousands) Initial staging 151 BCR 460 143 RLT selection 58 Monitoring for mCRPC progression Monitoring response to RLT 71 52 Response to treatment nmCRPC Disease progression Current indications Future indications Total addressable market Current TAM: ~670,000 scans/year 20 TAM = Total addressable market, BCR = Biochemical recurrence, nmCRPC = non-metastatic castration-resistant prostate cancer, RLT = Radioligand therapy. ClinicalTrials.gov: NCT07052214. Annual PSMA-PET scan volume in the U.S. based on internal estimates. Current state: PSMA-PET transformed staging and BCR detection Initial biopsy protocol has remained unchanged since the addition of MRI

BCR RLT selection Monitoring for mCRPC progression Monitoring response to RLT Response to treatment nmCRPC (pre-biopsy) Move imaging utilization to the pre-biopsy stage Disease progression Current indications Future indications Total addressable market Initial staging eliminated 1M+1 ~800,000 scans/year 21 1. Estimate one million biopsies performed in the U.S. each year. Source: Filho et al. Adv Urol. 2022. ClinicalTrials.gov: NCT07052214. BiPASS = Biopsy of the Prostate Avoidance Stratification Study, TAM = Total addressable market, RLT = radioligand therapy Annual PSMA-PET scan volume in the U.S. based on internal estimates. Future state: revolutionizes biopsy decision-making Potential to double the size of the existing PSMA market

Therapeutics update and outlook Dr. David N. Cade Chief Medical Officer

23 Pipeline: Late-stage and “next-generation” assets PSMA: Prostate-specific membrane antigen. CAIX: Carbonic anhydrase IX. LAT1: L-Type amino acid transporter 1. CD66: Cluster of differentiation 66. PDGFRα: Platelet-derived growth factor receptor alpha. mAb: Monoclonal antibody. SM: Small molecule. FAP: Fibroblast activation protein.

24 Progressing across early and late-stage therapeutics pipeline Select pipeline highlights Phase 3 study for TLX591-Tx for mCRPC reached alignment with FDA on safety data to progress to Part 21 TLX597-Tx, Phase 2 study for mCRPC completed enrollment in OPTIMAL-PSMA5, 120 patients, and started dosing patients in OPTIMAL-e for mHSPC6 TLX101-Tx2, Phase 3 study for glioblastoma completed enrollment of first cohort TLX250-Tx, Phase 2/3 study for ccRCC3 started dosing patients TLX090-Tx4, Phase 1 study for bone pain in patients with osteoblastic lesions continues enrolling patients Collaboration with Regeneron focused on alpha therapies, including targets for lung cancer7 Delivering on our late-stage pipeline Advancing our earlier stage candidates 1. Telix ASX disclosure July 2, 2026. ClinicalTrials.gov ID: NCT06520345. 2. ClinicalTrials.gov ID: NCT07100730. 3. ClinicalTrials.gov ID: NCT07197580. 4. ClinicalTrials.gov ID: NCT07197645. 5. Telix LinkedIn June 25, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437. 6. Telix media release July 16, 2026. Australian New Zealand Clinical Trials Registry ID: ACTRN12626000034336. 7. Telix ASX disclosure April 13, 2026.

25 Our multi-product prostate cancer therapy portfolio Hormone-sensitive Castration-resistant PSA tumor burden1 mHSPC 33,600 Metastatic castration-resistant 3L+ mCRPC 14,300 2L mCRPC 21,700 1L mCRPC 32,100 Global TLX591-Tx Phase 2a in PSMA+ mHSPC patients TLX597-Tx OPTIMAL-e Annual incidence, U.S. patients2 TLX592-Tx TLX090-Tx PalliativeMetastatic hormone-sensitive Phase 3 in PSMA+ mCRPC patients previously treated with 1 ARPI Telix’s multi-product portfolio addresses different stages of prostate cancer 1. Illustrative of fluctuating PSA levels at different stages of disease progression. 2. Adapted from Calais J. UCLA 2023 EANM 2023. All figures reflect 2026 estimates. Clarivate Market Forecast, published July 2025. Aligned to disease state, patient needs and clinical opportunity

26 Select milestones for Therapeutics candidates Select milestones for Precision Medicine candidates Select milestones for Telix Manufacturing Solutions TLX591-Tx for mCRPC, ProstACT Global • Part 1 data readout • Part 2 international site expansion, interim analysis1 TLX250-Tx for ccRCC, LUTEON, patient dosing TLX090-Tx for metastatic bone pain, SOLACE, enrollment completion TLX592-Tx for mCRPC, AlphaPRO, patient dosing TLX102-Tx for recurrent GBM and leptomeningeal disease, trial commencement TLX252-Tx for ccRCC and other CAIX-expressing tumors, trial commencement TLX400-Tx recommencement of clinical activity Pixclara2 NDA resubmission (U.S.) Zircaix2 BLA resubmission (U.S.) BiPASS enrollment completion Illuccix Japan, enrollment completion Illuccix China, regulatory approval/launch TLX593-Px (AlFluor ) trial commencement Commence cyclotron installations at key RLS sites 50 ARTMS QIS® installations globally TLX101-Tx for recurrent GBM • IPAX BrIGHT, first patient cohort dosed • IPAX 2- data readout MTD (Max tolerated dose) Regeneron collaboration Pixlumi2 MAA submission (Europe) TLX597-Tx for mCRPC, OPTIMAL-PSMA, enrollment completion. OPTIMAL-e, patient dosing A catalyst rich 2026 Pixclara2 IND submission for new indication TMS North Melbourne site opening QIS = QUANTM irradiation system, a cyclotron-based isotope production system. NDA = New drug application, MAA = Marketing authorization application, IND = Investigational new drug. 1. Protocol 177Lu-TLX591-203. 2. Brand name subject to final regulatory approval.

Q&A